646 related articles for article (PubMed ID: 33406487)
1. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Daly MB; Pal T; Berry MP; Buys SS; Dickson P; Domchek SM; Elkhanany A; Friedman S; Goggins M; Hutton ML; ; Karlan BY; Khan S; Klein C; Kohlmann W; ; Kurian AW; Laronga C; Litton JK; Mak JS; ; Menendez CS; Merajver SD; Norquist BS; Offit K; Pederson HJ; Reiser G; ; Senter-Jamieson L; ; Shannon KM; Shatsky R; Visvanathan K; Weitzel JN; Wick MJ; Wisinski KB; Yurgelun MB; Darlow SD; Dwyer MA
J Natl Compr Canc Netw; 2021 Jan; 19(1):77-102. PubMed ID: 33406487
[TBL] [Abstract][Full Text] [Related]
2. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
Daly MB; Pal T; Maxwell KN; Churpek J; Kohlmann W; AlHilli Z; Arun B; Buys SS; Cheng H; Domchek SM; Friedman S; Giri V; Goggins M; Hagemann A; Hendrix A; Hutton ML; Karlan BY; Kassem N; Khan S; Khoury K; Kurian AW; Laronga C; Mak JS; Mansour J; McDonnell K; Menendez CS; Merajver SD; Norquist BS; Offit K; Rash D; Reiser G; Senter-Jamieson L; Shannon KM; Visvanathan K; Welborn J; Wick MJ; Wood M; Yurgelun MB; Dwyer MA; Darlow SD
J Natl Compr Canc Netw; 2023 Oct; 21(10):1000-1010. PubMed ID: 37856201
[TBL] [Abstract][Full Text] [Related]
3. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
4. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
[TBL] [Abstract][Full Text] [Related]
5. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
Daly MB; Pilarski R; Yurgelun MB; Berry MP; Buys SS; Dickson P; Domchek SM; Elkhanany A; Friedman S; Garber JE; Goggins M; Hutton ML; Khan S; Klein C; Kohlmann W; Kurian AW; Laronga C; Litton JK; Mak JS; Menendez CS; Merajver SD; Norquist BS; Offit K; Pal T; Pederson HJ; Reiser G; Shannon KM; Visvanathan K; Weitzel JN; Wick MJ; Wisinski KB; Dwyer MA; Darlow SD
J Natl Compr Canc Netw; 2020 Apr; 18(4):380-391. PubMed ID: 32259785
[TBL] [Abstract][Full Text] [Related]
6. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
[TBL] [Abstract][Full Text] [Related]
7. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Shulman LP
Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
[TBL] [Abstract][Full Text] [Related]
8. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
Doren A; Vecchiola A; Aguirre B; Villaseca P
Climacteric; 2018 Dec; 21(6):529-535. PubMed ID: 30295091
[TBL] [Abstract][Full Text] [Related]
9. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
Daly MB; Pilarski R; Axilbund JE; Berry M; Buys SS; Crawford B; Farmer M; Friedman S; Garber JE; Khan S; Klein C; Kohlmann W; Kurian A; Litton JK; Madlensky L; Marcom PK; Merajver SD; Offit K; Pal T; Rana H; Reiser G; Robson ME; Shannon KM; Swisher E; Voian NC; Weitzel JN; Whelan A; Wick MJ; Wiesner GL; Dwyer M; Kumar R; Darlow S
J Natl Compr Canc Netw; 2016 Feb; 14(2):153-62. PubMed ID: 26850485
[TBL] [Abstract][Full Text] [Related]
10. Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.
Jacobs C; Pichert G; Harris J; Tucker K; Michie S
Psychooncology; 2017 Nov; 26(11):1818-1824. PubMed ID: 28101941
[TBL] [Abstract][Full Text] [Related]
11. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
12. Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis.
Quinn GP; Vadaparampil ST; Bower B; Friedman S; Keefe DL
Minerva Med; 2009 Oct; 100(5):371-83. PubMed ID: 19910890
[TBL] [Abstract][Full Text] [Related]
13. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.
Lorenzo Bermejo J; Hemminki K
Ann Oncol; 2004 Dec; 15(12):1834-41. PubMed ID: 15550590
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
15. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
Sorscher S; Ansley K; Delaney SD; Ramkissoon S
Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
[TBL] [Abstract][Full Text] [Related]
16. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.
Nelson HD; Huffman LH; Fu R; Harris EL;
Ann Intern Med; 2005 Sep; 143(5):362-79. PubMed ID: 16144895
[TBL] [Abstract][Full Text] [Related]
17. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K
J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168
[TBL] [Abstract][Full Text] [Related]
18. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
[TBL] [Abstract][Full Text] [Related]
19. Familial breast and ovarian cancers.
Arai M; Utsunomiya J; Miki Y
Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
[TBL] [Abstract][Full Text] [Related]
20. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.
Nelson HD; Pappas M; Zakher B; Mitchell JP; Okinaka-Hu L; Fu R
Ann Intern Med; 2014 Feb; 160(4):255-66. PubMed ID: 24366442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
